{"entity":{"id":"nct05751928","kind":"trial","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","aka":[],"tldr":"A phase 3 trial testing BCD-217 in melanoma, active and no longer recruiting.","summary":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma is a phase 3 interventional study registered as NCT05751928, led by Biocad, and active but no longer recruiting on the registry. Official title: A Randomised Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma. Planned enrolment is 411 participants (actual). The study started in 2023-04-05 and primary completion is expected in 2027-01. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05751928","url":"https://clinicaltrials.gov/study/NCT05751928"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma","stage-iii-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["bcd-217"],"companies":["biocad"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05751928","phase":"3","setting":"A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma","sponsor":"Biocad","participation":[{"nct":"NCT05751928","source":"https://clinicaltrials.gov/study/NCT05751928","fetchedAt":"2026-10-07T16:53:54.339Z","studySha256":"b1c77fb7b97ab95b054b8531f8eb4f99127d6a0e17108dd74ae2c303931fafa9","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-07-08","leadSponsor":"Biocad","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":411,"enrolmentType":"ACTUAL","siteCount":36,"recruitingSiteCount":0,"countries":["Belarus","Russia"]}],"started":"2023-04-05","startedType":"actual","enrolled":411,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05751928/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"drug":[{"id":"bcd-217","kind":"drug","name":"BCD-217","route":"/drugs/bcd-217/"}],"company":[{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/"}]}}